Search
for
Sort by
Research 721–750 of 1000+
- The association between rs2476601 polymorphism in PTPN22 gene and risk of alopecia areata
- Hidradenitis suppurativa: A comparison of guidelines
- The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy
- Understanding skin morphogenesis across developmental, regenerative and evolutionary levels
- Efficacy of Human Foreskin Fibroblast–Conditioned Medium in the Treatment of Androgenic Alopecia: A Pilot Trial
- A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia
- Camellia japonica seed extract promotes hair growth by preventing dermal papilla cell senescence and activating hair follicle stem cells
- Exosome as a Therapeutic Agent in Cosmetic Dermatology
- Managing patterned hair loss – a hair raising task!
- Clinical Use of Extracellular Vesicles in the Management of Male and Female Pattern Hair Loss: A Preliminary Retrospective Institutional Review Board Safety and Efficacy Study
- Pharmacokinetics of two different formulations of finasteride (topical and oral) in male volunteers with androgeneic alopecia
- Epidermal Nevi
- Keratinization of sheath and calamus cells in developing and regenerating feathers
- Cronkhite–Canada syndrome: from clinical features to treatment
- Hair
- Male Androgenetic Alopecia — Endotext
- Effect of COVID-19 on Hair Diseases Observed by Health Care Providers: Analysis of 513 participants
- Nanotechnology-based techniques for hair follicle regeneration
- Regeneration of fat cells from myofibroblasts during wound healing
- Comparitive Effectiveness and Finasteride <i>Vs Serenoa Repens</i> in Male Androgenetic Alopecia: A Two-Year Study
- Current Status of Fractional Laser Resurfacing
- Trichohyalin: Presence in the Granular Layer and Stratum Corneum of Normal Human Epidermis
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Finasteride for the Treatment of Hidradenitis Suppurativa in Children and Adolescents
- Part II. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
- A systematic review and meta‐synthesis of qualitative studies of alopecia: Managing identity and appearance changes